Clinical trials: Impairment
Mild Cognitive Impairment
Effect of Nutritional Supplementation With Turmeric on the Cognitive Performance of Subjects With Metabolic Syndrome
The EPICURO study aims to demonstrate the beneficial effects of a 6-month dietary supplementation with an improved bioavailable turmeric (MERIVA®) on inflammatory, oxidative and metabolic parameters together with cognitive…
- Trial name
- EPICURO (NCT04705220)
- Testing
- MERIVA® Tablets
- Where
- Italy
- Volunteers
- 85 people
- Sponsor
- Indena S.p.A
Hepatic Insufficiency
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
Evaluate simufilam levels in the blood of hepatically impaired individuals compared to Healthy individuals of similar demographics
- Trial name
- NCT06390410
- Testing
- Simufilam
- Where
- 3 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Cassava Sciences, Inc.
Cognitive Impairment Associated With Schizophrenia
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB).
- Trial name
- TALLY (NCT03745820)
- Testing
- BIIB104
- Where
- 60 sites in United States, Germany and 3 more
- Volunteers
- 195 people
- Sponsor
- Biogen
Heart Failure, Renal Insufficiency
Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment
CNDP-578-02 is a randomized, double-blind, placebo-controlled, dose-escalation, crossover design trial. Eight evaluable subjects (n=8) with chronic stable heart failure and moderate renal impairment will be randomized (1:1) to…
- Trial name
- NCT02603614
- Testing
- Cenderitide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Capricor Inc.
Diabetes Mellitus, Type 2
A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease
Participants will receive one insulin icodec dose, which will be administered in the morning of the day of dosing. The study will last for about 8 weeks.
- Trial name
- NCT04597697
- Testing
- Insulin icodec
- Where
- 2 sites in Czechia, Slovakia
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Schizophrenia, Impaired Cognition
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies…
- Trial name
- NCT01714713
- Testing
- EVP-6124
- Where
- 128 sites in United States, Argentina and 14 more
- Volunteers
- 830 people
- Sponsor
- FORUM Pharmaceuticals Inc
Impaired Glucose Tolerance
HSK7653 in Chinese Patients with Impaired Glucose Tolerance
This study is being done to evaluate the efficacy, safety of HSK7653 in chinese participants with impaired glucose tolerance.
- Trial name
- NCT04727580
- Testing
- HSK7653 10mg Q2W, HSK7653 25mg Q2W
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Renal Impairment
Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function
The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood of individuals with severe renal impairment compared to individuals…
- Trial name
- NCT01526746
- Testing
- Tasimelteon
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Cardiovascular Disease
A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants
The purpose of this study is to measure how much of the study drug, evacetrapib, enters the blood stream and how long it takes the body to dispose of the study drug when given to participants with severe renal (kidney) impairment…
- Trial name
- NCT01825889
- Testing
- Evacetrapib
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.
- Trial name
- NCT02997176
- Testing
- Talazoparib
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Pfizer
Renal Insufficiency
Afatinib in Subjects With Kidney Dysfunction
The primary objective of the current study is to investigate the influence of moderate to severe renal impairment on the pharmacokinetics and safety of a single dose afatinib in comparison to a control group with normal renal…
- Trial name
- NCT02096718
- Testing
- Afatinib healthy, Afatinib severe renally impaired, Afatinib moderate renally impaired
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cognitive Impairment
A Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training Programme in Europe
This is a study to determine the effectiveness of the VIZAMYL™ reader training programme in clinical practice in Europe
- Trial name
- NCT04773015
- Where
- 10 sites in Austria, Finland and 3 more
- Volunteers
- 227 people
- Sponsor
- GE Healthcare
Traumatic Brain Injury
Traumatic Brain Injury Peripheral Nerve Study
Peripheral nerve stimulation for the treatment of sequelae due to traumatic brain injury. This study will specifically examine patients with mild traumatic brain injury (TBI) who have persistent cognitive impairments lasting one…
- Trial name
- TBI (NCT01588691)
- Testing
- Eon-mini IPG (implantable pulse generator)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abbott Medical Devices
Acute Heart Failure (AHF)
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard…
- Trial name
- RELAX-AHF-EU (NCT02064868)
- Testing
- Serelaxin, Standard of Care
- Where
- 357 sites in Austria, Belgium and 23 more
- Volunteers
- 2,666 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.
- Trial name
- NCT02063230
- Testing
- Selumetinib 50mg, Selumetinib 25mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cognitive Impairment, Mild Cognitive Impairment
Assessing Performance on Speech Tasks Via Crowdsourced Participants
The purpose of the study is to examine the properties of the Automatic Story Recall Test (ASRT) and its parallel variants, as well as letter fluency and category fluency cognitive tests.
- Trial name
- AMYWEB (NCT05298501)
- Testing
- No intervention/exposure
- Where
- United Kingdom
- Volunteers
- 1,034 people
- Sponsor
- Novoic Limited
Analgesic Allergy
Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function
The primary objective of this study is to evaluate the potential effect of hepatic impairment on the systemic pharmacokinetics of RX0041-002 following single dose intranasal administration.
- Trial name
- NCT02775981
- Testing
- RX0041-002
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pharmaceutical Project Solutions, Inc.
Healthy Aging, Dietary Supplement
Effect of BrainPhyt, a Microalgae Based Ingredient on Cognitive Function in Healthy Older Subjects
In developed countries, the acceleration of the general population ageing has been widely described for decades, involving changes in public health policies.
- Conditions
- Healthy Aging, Dietary Supplement, Fucoxanthin, Cognitive Impairment
- Trial name
- PHAEOSOL-THREE (NCT04832412)
- Testing
- BrainPhyt, 100 % Maltodextrin
- Where
- Ireland
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Microphyt
Parkinson Disease
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive…
- Trial name
- NCT03713957
- Testing
- GRF6021
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Alkahest, Inc.
Hepatic Impairment
A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment
The primary purpose of this study is to evaluate the effect of liver impairment on the safety and pharmacokinetics (PK) of BMS-986263
- Trial name
- NCT04225936
- Testing
- BMS-986263
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.